Analyst upgrades typically lead to positive short-term price movements. The substantial increase in the price target from $90 to $115 by a reputable firm like Morgan Stanley suggests a strong confidence in Axsome Therapeutics' future performance, likely leading to increased investor interest and a potential rise in stock price.